PerkinElmer Expands Cell Biology Capabilities with Acquisition of Nexcelom Bioscience
This acquisition gives PerkinElmer access to the complementary cell counting and analysis capabilities of Nexcelom Bioscience and improves its QA / QC capabilities.
PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience, a US supplier of image cytometry products for cell analysis, for $ 260 million in cash. The transaction is expected to close in the second quarter of 2021, PerkinElmer said in a May 12, 2021 press release.
Nexcelom provides automated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents. It also provides consumables and instructions for the selection and development of fit-for-use cell counting methods that comply with ISO cell counting standards and that facilitate the development of cell, gene and immuno-oncology therapies, virological drugs. and vaccines.
The deal follows PerkinElmer’s recent $ 383 million acquisition of Horizon Discovery Group, a UK cell engineering company specializing in gene editing and modulation (1).
“We look forward to combining Nexcelom’s expertise and technologies in drug development with our passion and solutions for drug discovery. This combination will expand our efforts to help academic, government and biopharmaceutical organizations streamline their entire workflows and support efforts to accelerate the targeting time and time to market for new therapies, ”said Prahlad Singh, president and CEO of PerkinElmer, in the company press. Release.
“Our team is very excited to partner with PerkinElmer to help scientists solve some of today’s most pressing health challenges by modernizing cell testing using the most advanced cell models. Our organization is deeply committed to innovation and we look forward to continuing to grow our technology and our customer footprint in combination with PerkinElmer’s strong global presence and infrastructure, ”added Peter Li, President and CEO of Nexcelom, in the press release.
1. PerkinElmer, “PerkinElmer to Acquire Cellular Engineering Company Horizon Discovery for $ 383million (£ 296million),” press release, November 2, 2020.